Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 301–400 of 1,031
Retinal gene therapy: surgical vector delivery in the translation to clinical trials
Ochakovski, G. A., Bartz-Schmidt, K. U., & Fischer, M. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00174 · Cited by 110
“Since gene therapy can only be successful if the target cells are still viable, disease type, and stage need to be considered when choosing the application approach.”
BackgroundHeparin binding induces conformational changes in Adeno-associated virus serotype 2
Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., et al. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2008.12.002 · Cited by 110
“Extrusion and activity of the VP1-N terminal PLA2 domain is essential for efficient infection and is believed to occur during or shortly after virus entry into the cell (Bleker et al., 2005; Farr et al., 2006; Mani et al., 2006; Suikkanen et al., 2003; Vihinen-Ranta et al., 2002).”
BackgroundPatel, P., Kriz, J., Gravel, M., Soucy, G., Bareil, C., Gravel, C., & Julien, J.-P. (2014) · Molecular Therapy · doi:10.1038/mt.2013.239 · Cited by 110
Dalkara, D., Kolstad, K. D., Guerin, K. I., Hoffmann, N. V., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.62 · Cited by 110
Garanto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 110
Self-citationRetinitis Pigmentosa: Progress and Perspective
Zhang, Q. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000227 · Cited by 109
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 109
Self-citationAnimal Models of Retinal Disease
Fletcher, E. L., Jobling, A. I., Vessey, K. A., Luu, C. D., Guymer, R. H., & Baird, P. N. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00006-6 · Cited by 120
Human Cone Visual Pigment Deletions Spare Sufficient Photoreceptors to Warrant Gene Therapy
Cideciyan, A. V., Hufnagel, R. B., Carroll, J., Sumaroka, A., Luo, X., Schwartz, S. B., Dubra, A., Land, M., Michaelides, M., Gardner, J. C., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.153 · Cited by 110
“Previous human trials using gene delivery by subretinal injection have documented loss of foveal outer segments and cone cells after this procedure (Hauswirth et al. , 2008; Maguire et al. , 2008; Jacobson et al. , 2012).”
Retinitis Pigmentosa and Allied Disorders
Gregory-Evans, K., Pennesi, M. E., & Weleber, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00040-0 · Cited by 122
Mowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Cai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109
“. Results from these studies have prompted three successful and ongoing human clinical trials”
ResultMao, Y., Wang, X., Yan, R., Hu, W., Li, A., Wang, S., & Li, H. (2016) · BMC Biotechnology · doi:10.1186/s12896-015-0230-0 · Cited by 109
“For instance, AAV2-mediated RPE65 gene transfer conferred safe and efficient improvement in retinal function in Leber’s Congenital Amaurosis patients by subretinal injection [8, 9].”
BackgroundEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
“…all 12 patients who received a subretinal injection of AAV2 encoding a protein required for the isomerohydrolase activity of retinal pigment epithelium showed sustained improvement in both subjective and objective measurements of vision (Bainbridge et al., 2008; Maguire et al., 2008, 2009).”
BackgroundGene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
“Indeed, RPE65-LCA clinical trials were initiated in 2007 by groups from the United Kingdom and the United States [83,160,161] following the encouraging results of animal studies.”
BackgroundRetinoids and Retinal Diseases
Kiser, P. D., & Palczewski, K. (2016) · Annual Review of Vision Science · doi:10.1146/annurev-vision-111815-114407 · Cited by 108
“…protein investigation: RPE65 gene therapy to restore a functional RPE-based retinoid cycle (Acland et al. 2001, Bainbridge et al. 2008, Maguire et al. 2008) and treatment with an artificial chromophore (9-cis-RAL) to bypass the metabolic blockade caused by the lack of RPE65 activity…”
Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration
Molday, R. S., Garces, F. A., Scortecci, J. F., & Molday, L. L. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101036 · Cited by 107
Adijanto, J., Castorino, J. J., Wang, Z.-X., Maminishkis, A., Grunwald, G. B., & Philp, N. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.354761 · Cited by 106
Beltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96
Nanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105
“(2) who experienced an increase in NAb titer which then decreased to a level slightly above baseline.”
BackgroundMethodInfluentialSelf-citationCell transplantation strategies for retinal repair
West, E. L., Pearson, R. A., MacLaren, R. E., Sowden, J. C., & Ali, R. R. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17501-5 · Cited by 114
“Future treatment for retinal degeneration due to photoreceptor cell loss may require a combination of gene and cell therapeutic strategies (Bainbridge et al., 2008; Maguire et al., 2008).”
BackgroundEvaluation of AAV-Mediated Expression of Chop2-GFP in the Marmoset Retina
Ivanova, E., Hwang, G.-S., Pan, Z.-H., & Troilo, D. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5389 · Cited by 105
Wiley, L. A., Burnight, E. R., Songstad, A. E., Drack, A. V., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.10.002 · Cited by 124
“Gene augmentation is an effective strategy to treat inherited retinal dystrophies, the causes of which are mutations in enzymes or other small genes easily packaged into the well-characterized and efficient adeno-associated virus (AAV) vectors.”
BackgroundInfluentialSelf-citationHuman gene therapy: a brief overview of the genetic revolution.
Misra, S. (2013) · PubMed · Cited by 161
Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103
Self-citationKoenekoop, R. K., Sui, R., Sallum, J., van den Born, L. I., Ajlan, R., Khan, A., den Hollander, A. I., Cremers, F. P. M., Mendola, J. D., Bittner, A. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60153-7 · Cited by 103
Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration
Zhang, L., Du, J., Justus, S., Hsu, C.-W., Bonet-Ponce, L., Wu, W.-H., Tsai, Y.-T., Wu, W.-P., Jia, Y., Duong, J. K., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86905 · Cited by 103
AAV-mediated photoreceptor transduction of the pig cone-enriched retina
Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.3 · Cited by 102
Self-citationDerivation of Traceable and Transplantable Photoreceptors from Mouse Embryonic Stem Cells
Decembrini, S., Koch, U., Radtke, F., Moulin, A., & Arsenijévic, Y. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.04.010 · Cited by 107
Koilkonda, R. D., Yu, H., Chou, T.-H., Feuer, W. J., Ruggeri, M., Porciatti, V., Tse, D., Hauswirth, W. W., Chiodo, V., Boye, S. L., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7630 · Cited by 103
Jo, D. H., Song, D. W., Cho, C. S., Kim, U. G., Lee, K. J., Lee, K., Park, S. W., Kim, D., Kim, J. H., Kim, J.-S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax1210 · Cited by 102
Retinal remodeling in the Tg P347L rabbit, a large‐eye model of retinal degeneration
Jones, B. W., Kondo, M., Terasaki, H., Watt, C. B., Rapp, K. D., Anderson, J., Lin, Y., Shaw, M. V., Yang, J., & Marc, R. E. (2011) · The Journal of Comparative Neurology · doi:10.1002/cne.22703 · Cited by 110
“However, they are desirable for surgical interventions, subretinal injections of gene therapies (Acland et al., 2001; Bainbridge et al., 2008; Maguire et al., 2008), survival factors (Faktorovich et al., 1990, 1992; Zeiss et al., 2006; Beltran et al., 2007), cells or cellular components (Young et…”
BackgroundIntravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery
Hartman, R. R., & Kompella, U. B. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0121 · Cited by 100
Photoreceptor Layer Topography in Children with Leber Congenital Amaurosis Caused by RPE65 Mutations
Jacobson, S. G., Cideciyan, A. V., Aleman, T. S., Sumaroka, A., Windsor, E. A. M., Schwartz, S. B., Heon, E., & Stone, E. M. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2121 · Cited by 101
Self-citationThompson, D. A., Ali, R. R., Banin, E., Branham, K. E., Flannery, J. G., Gamm, D. M., Hauswirth, W. W., Heckenlively, J. R., Iannaccone, A., Jayasundera, K. T., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16049 · Cited by 101
A History Lesson for Stem Cells
Wilson, J. M. (2009) · Science · doi:10.1126/science.1174935 · Cited by 101
Capsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Self-citationConlon, T. J., Deng, W.-T., Erger, K., Cossette, T., Pang, J.-J., Ryals, R., Clément, N., Cleaver, B., McDoom, I., Boye, S. E., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.037 · Cited by 99
“The results from three separate Phase I clinical trials for Leber’s congenital amaurosis type 2 demonstrated the safety of AAV2 in human patients (Bainbridge et al., 2008; Cideciyan et al., 2008; Maguire et al., 2008).”
ResultGene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G.-S. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 100
Carroll, J., Dubra, A., Gardner, J. C., Mizrahi‐Meissonnier, L., Cooper, R. F., Dubis, A. M., Nordgren, R. N., Genead, M. A., Connor, T. B., Stepien, K. E., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11087 · Cited by 106
“Implications for Restoration of Visual Function in Subjects with OPN1LW and OPN1MW Mutations Advances in gene therapy have generated a great deal of excitement regarding the restoration of cone function in a variety of retinal diseases.(42-48) While subjects with L/M interchange mutations had the greatest degree of re…”
Lock, M., Alvira, M. R., & Wilson, J. M. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.217 · Cited by 99
“…hereditary eye defect, Leber’s congenital amaurosis (Kaplitt et al. , 2007; Bainbridge et al. , 2008; Eberling et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008, 2009; Christine et al. , 2009; Simonelli et al. , 2010), has led to an upsurge of interest and high expectations for…”
Takahashi, K., Igarashi, T., Miyake, K., Kobayashi, M., Yaguchi, C., Iijima, O., Yamazaki, Y., Katakai, Y., Miyake, N., Kameya, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.008 · Cited by 99
“Moreover, several adverse effects, including foveal thinning, macular holes, choroidal effusion, and ocular hypo- or hypertension have been observed during the immediate postoperative days.(2,3,8,9) Consequently, subretinal injection can potentially lead to permanent visual dysfunction.”
BackgroundHomma, K., Okamoto, S., Mandai, M., Gotoh, N., Rajasimha, H. K., Chang, Y.-S., Chen, S., Li, W., Cogliati, T., Swaroop, A., et al. (2013) · Stem Cells · doi:10.1002/stem.1372 · Cited by 106
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
Ernst, M. P. T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.022 · Cited by 108
Chiu, W., Lin, T.-Y., Chang, Y.-C., Lai, H. I. A. M., Lin, S.-C., Ma, C., Yarmishyn, A. A., Lin, S.-C., Chang, K.-J., Chou, Y.-B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094534 · Cited by 116
“Although one patient developed an asymptomatic macular hole, which is an adverse event, the retinal function was nevertheless restored [48].”
BackgroundInfluentialMohan, R. R., Gupta, R., Mehan, M. M., Cowden, J. W., & Sinha, S. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.05.013 · Cited by 104
“Successful restoration of vision in human patients with gene therapy affirms its promise to cure ocular diseases and prevent blindness [Bainbridge et al., 2008; Maguire et al., 2008].”
BackgroundBasic FGF or VEGF gene therapy corrects insufficiency in the intrinsic healing capacity of tendons
Tang, J. B., Wu, Y. F., Cao, Y., Chuan-hao, C., Zhou, Y. L., Avanessian, B. K., Shimada, M., Wang, X. T., & Liu, P. Y. (2016) · Scientific Reports · doi:10.1038/srep20643 · Cited by 110
Choi, E. H., Suh, S., Foik, A. T., Leinonen, H., Newby, G. A., Gao, X. D., Banskota, S., Hoang, T., Du, S. W., Dong, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29490-3 · Cited by 96
Viral Vectors for Gene Transfer: Current Status of Gene Therapeutics
Heilbronn, R., & Weger, S. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00477-3_5 · Cited by 112
Cecchini, S., Virag, T., & Kotin, R. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.250 · Cited by 97
“For diseases treatable with locoregional administration of rAAV, e.g., subretinal injection for treating Leber’s congenital amaurosis (Bennicelli et al., 2008; Maguire et al., 2008, 2009), therapeutic doses of rAAV are readily obtained from a relatively small number of rAAV producer cells.”
BackgroundBiomedical Engineering - Technical Applications in Medicine
Hudák, R., Penhaker, M., & Majerník, J. (2012) · InTech eBooks · doi:10.5772/2608 · Cited by 104
AAV9 targets cone photoreceptors in the nonhuman primate retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053463 · Cited by 97
“All human applications of AAV gene transfer to the retina, and most other target organs, have utilized vectors based on serotype 2 (AAV2) [7,8,9].”
BackgroundSelf-citationQuinn, P. M., Buck, T. M., Mulder, A. A., Ohonin, C., Alves, C. H., Vos, R. M., Bialecka, M., van Herwaarden, T., van Dijk, E. H. C., Talib, M., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.002 · Cited by 97
“Some retinal gene therapies use a serotype of AAV as a delivery vector in clinical trials (MacLaren et al., 2014; Maguire et al., 2008; Reichel et al., 2018) because it restricts vector tropism to specific retinal subpopulations, improves the efficiency of gene delivery, has low immunogenicity and long transgene expre…”
BackgroundMiyadera, K., Acland, G. M., & Aguirre, G. D. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9361-3 · Cited by 113
Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96
“Adeno-associated virus (AAV) vectors have been safely and successfully used in phase I clinical trials (39, 40, 54).”
MethodStructural insights into adeno-associated virus serotype 5
Govindasamy, L., DiMattia, M. A., Gurda, B. L., Halder, S., McKenna, R., Chiorini, J. A., Muzyczka, N., Zolotukhin, S., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.00867-13 · Cited by 95
Boye, S. E., Boye, S. L., Pang, J., Ryals, R., Everhart, D., Umino, Y., Neeley, A. W., Besharse, J., Barlow, R., & Hauswirth, W. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011306 · Cited by 94
“CBA has been shown to be safe, effective and persistent when used in proof of concept experiments and in clinical trials of retinal disease [14],[31],[39]–[40],[45],[49], [55]–[56] and is perhaps better suited for translation into the clinic.”
BackgroundKoo, T., Park, S. W., Jo, D. H., Kim, D., Kim, J. H., Cho, H.-Y., Kim, J., Kim, J. H., & Kim, J.-S. (2018) · Nature Communications · doi:10.1038/s41467-018-04175-y · Cited by 95
The genetics and pathogenesis of CAKUT
Kolvenbach, C. M., Shril, S., & Hildebrandt, F. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00742-9 · Cited by 112
“This approach is aimed at replacing the missing gene product through a viral vector brought into the cell of disease origin 168–172 .”
Gene therapy of inherited diseases
Fischer, A., & Cavazzana, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60874-0 · Cited by 117
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
Self-citationDrack, A. V., Dumitrescu, A. V., Bhattarai, S., Gratie, D., Stone, E. M., Mullins, R., & Sheffield, V. C. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8544 · Cited by 94
Self-citationAyuso, E., Blouin, V., Lock, M., McGorray, S., Leon, X., Alvira, M. R., Auricchio, A., Bucher, S., Chtarto, A., Clark, K. R., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.057 · Cited by 94
“…in humans using recombinant adeno-associated viral (rAAV) vectors for hemophilia B, Leber Congenital Amaurosis (LCA) and lipoprotein lipase deficiency (LPLD) among other diseases (Bainbridge et al., 2008; Gaudet et al., 2013; Maguire et al., 2008; Manno et al., 2006; Nathwani et al., 2011).”
BackgroundSelf-citationTrapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv386 · Cited by 94
Self-citationThe Role of Inflammation in Retinal Neurodegeneration and Degenerative Diseases
Kaur, G., & Singh, N. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010386 · Cited by 101
Duebel, J., Marazova, K., & Sahel, J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000140 · Cited by 123
Pharmacological approaches to retinitis pigmentosa: A laboratory perspective
Guadagni, V., Novelli, E., Piano, I., Gargini, C., & Strettoi, E. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.005 · Cited by 110
Lipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundSalmon, F., Grosios, K., & Petry, H. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 93
Optogenetic approaches to restoring visual function in retinitis pigmentosa
Busskamp, V., & Roska, B. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.06.001 · Cited by 98
Tee, J. J. L., Smith, A. J., Hardcastle, A. J., & Michaelides, M. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307698 · Cited by 94
PABPN1 gene therapy for oculopharyngeal muscular dystrophy
Malerba, A., Klein, P., Bachtarzi, H., Jarmin, S. A., Cordova, G., Ferry, A., Strings, V., Espinoza, M. P., Mamchaoui, K., Blumen, S. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14848 · Cited by 89
Thompson, D. A., Iannaccone, A., Ali, R. R., Arshavsky, V. Y., Audo, I. S., Bainbridge, J. W., Besirli, C. G., Birch, D. G., Branham, K. E. H., Cideciyan, A. V., et al. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.2 · Cited by 101
Self-citationTherapeutic Potential of Small Molecules and Engineered Proteins
Gurevich, E. V., & Gurevich, V. V. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-41199-1_1 · Cited by 92
“was delivered to the pigment epithelium of Leber’s congenital amaurosis patients carrying loss-of-function mutations in this protein (Cideciyan et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008; Bainbridge et al. 2008) demonstrate that gene delivery methods are ready for use today, not in the distant future (Cid…”
BackgroundDisease Boundaries in the Retina of Patients with Usher Syndrome Caused by MYO7A Gene Mutations
Jacobson, S. G., Aleman, T. S., Sumaroka, A., Cideciyan, A. V., Roman, A. J., Windsor, E. A. M., Schwartz, S. B., Rehm, H. L., & Kimberling, W. J. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3122 · Cited by 93
The optic nerve: A “mito-window” on mitochondrial neurodegeneration
Maresca, A., Morgia, C. L., Caporali, L., Valentino, M. L., & Carelli, V. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.08.004 · Cited by 106
Talib, M., van Schooneveld, M. J., Thiadens, A. A., Fiocco, M., Wijnholds, J., Florijn, R. J., Schalij-Delfos, N. E., van Genderen, M. M., Putter, H., Cremers, F. P. M., et al. (2019) · Retina · doi:10.1097/iae.0000000000002125 · Cited by 92
“Photophobia, n (%) 30 (41) 10/16 (63) 10/14 (71) Reported first symptom, n (%) 45 (61) 25 (48) 20 (91) Nyctalopia, n (%) 20 (44) 18 (72) 1 (5) Visual field loss, n (%) 2 (4) 2 (8) —”
Buie, L. K., Rasmussen, C. A., Porterfield, E. C., Ramgolam, V. S., Choi, V. W., Markovic-Plese, S., Samulski, R. J., Kaufman, P. L., & Borrás, T. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3847 · Cited by 92
Cremers, F., Boon, C., Bujakowska, K., & Zeitz, C. (2018) · Genes · doi:10.3390/genes9040215 · Cited by 91
Herson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N. B., Leturcq, F., Laforêt, P., Maisonobe, T., Amouri, R., Haddad, H., et al. (2012) · Brain · doi:10.1093/brain/awr342 · Cited by 91
“…have been completed, notably in Leber’s congenital amaurosis (with some clinical benefit) (Bainbridge et al., 2008; Cideciyan et al., 2008; Maguire et al., 2008, 2009), haemophilia B (Manno et al., 2003, 2006) and limb girdle muscular dystrophy type 2D ( -SGC deficiency) (Mendell et al.,…”
BackgroundGene therapy clinical trials worldwide to 2023—an update
Ginn, S. L., Mandwie, M., Alexander, I. E., Edelstein, M. L., & Abedi, M. R. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3721 · Cited by 113
Evading the immune response upon in vivo gene therapy with viral vectors.
Sack, B. K., & Herzog, R. W. (2009) · PubMed · Cited by 107
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 89
Tolmachova, T., Wavre-Shapton, S. T., Barnard, A. R., MacLaren, R. E., Futter, C. E., & Seabra, M. C. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4892 · Cited by 89
A Comprehensive Clinical and Biochemical Functional Study of a Novel RPE65 Hypomorphic Mutation
Lorenz, B., Poliakov, E., Schambeck, M., Friedburg, C., Preising, M. N., & Redmond, T. M. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1671 · Cited by 89
“The relative sparing of cone function may make this patient an ideal candidate for RPE65 somatic gene therapy, trials for which are currently in progress.(46,47)”
Self-citationMarella, M., Seo, B. B., Thomas, B. B., Matsuno-Yagi, A., & Yagi, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011472 · Cited by 89
“Together with the fact that the adeno-associated virus strategy was successfully used to treat retinal degeneration in human [46–48], it is conceivable that use of the NDI1 gene may prove to be a successful gene therapy to treat visual loss linked to mitochondrial optic neuropathy.”
BackgroundHauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88
Self-citationT Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
“In humans clinical trials targeting Leber’s congenital amaurosis, a congenital form of blindness, by small doses of AAV injected into the subretinal space reported long-term improvement of vision (6, 7).”
BackgroundTreatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Astuti, G., Bertelsen, M., Preising, M. N., Ajmal, M., Lorenz, B., Faradz, S. M., Qamar, R., Collin, R. W. J., Rosenberg, T., & Cremers, F. P. M. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.241 · Cited by 91
Ansari, M., Mckeigue, P. M., Skerka, C., Hayward, C., Rudan, I., Vitart, V., Polasek, O., Armbrecht, A.-M., Yates, J. R. W., Vatavuk, Z., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt336 · Cited by 88
“Therapeutic use of CFH delivered by 2-weekly intravenous injection of fresh frozen plasma (half-life 6 days) (46) is not practicable on the necessary scale, but local delivery of an inducible recombinant CFH to the choroid or retinal pigment epithelium by a viral vector may be more achievable (47,48).”
BackgroundRandomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
Stieger, K., Schroeder, J., Provost, N., Mendes-Madeira, A., Belbellaa, B., Meur, G. L., Weber, M., Deschamps, J.-Y., Lorenz, B., Moullier, P., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.283 · Cited by 88
Advances in implantable bionic devices for blindness: a review
Lewis, P. M., Ayton, L. N., Guymer, R. H., Lowery, A. J., Blamey, P. J., Allen, P. J., Luu, C. D., & Rosenfeld, J. V. (2016) · ANZ Journal of Surgery · doi:10.1111/ans.13616 · Cited by 87
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
Pellissier, L. P., Quinn, P. M., Alves, C. H., Vos, R. M., Klooster, J., Flannery, J. G., Heimel, J. A., & Wijnholds, J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv062 · Cited by 86
Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86
Dodiya, H. B., Bjorklund, T., Stansell III, J., Mandel, R. J., Kirik, D., & Kordower, J. H. (2010) · Molecular Therapy · doi:10.1038/mt.2009.216 · Cited by 86
Simons, D. L., Boye, S. L., Hauswirth, W. W., & Wu, S. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019222108 · Cited by 86
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.